QIAGEN earnings date and guidance
MyStockButler's October 2026 analysis: QIAGEN's next results are expected on November 4, 2026. QIAGEN's key watch is whether customers paid promptly and inventories absorbed cash.
What has QIAGEN guided for 2026?
Management guidance is the company’s public estimate of future sales and profit. Suspending it means QIAGEN is no longer promising a full-year result against which investors can judge performance. On October 21, 2026, the company reported preliminary third-quarter sales of $548 million and adjusted diluted EPS of $0.65. Adjusted earnings remove selected expenses; diluted EPS allows for shares that could be created through instruments such as employee awards. These preliminary figures do not replace the complete accounts.
The old 2026 promise had already weakened. In February, QIAGEN expected sales growth of at least 5% at constant exchange rates and adjusted diluted EPS of at least $2.50. By May, the targets had become roughly 1–2% sales growth and at least $2.43 EPS. Constant exchange rates, or CER, removes currency movements so investors can see whether the business sold more rather than merely translated sales at a favourable rate. Those targets are now historical reference points.
Has QIAGEN kept its past promises?
The completed-year record is mixed. Sales finished above the first promise twice, within it once and below it twice. Earnings were more dependable, while QuantiFERON, QIAGEN’s latent-tuberculosis test, exceeded its promise in every checked year.
| What management forecast | Checked | Above | Within | Below |
|---|---|---|---|---|
| Net sales | 5 years | 2 | 1 | 2 |
| Adjusted diluted EPS | 5 years | 4 | 0 | 1 |
| QuantiFERON | 4 years | 4 | 0 | 0 |
What do QIAGEN's last eight reported periods show?
In October 2026, QIAGEN announced preliminary Q3 sales of US$548 million. That was about 2.9% above the prior-year quarter. The company suspended its full-year outlook while the announced transaction was pending, and full results were scheduled for November 4. Sales had improved, but the accounts did not yet establish whether the improvement was organic, margin-accretive and cash-generative.
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 535,040 | 492,320 | 540,420 | 532,583 | 533,540 | 483,456 | 521,202 | 501,869 |
| Gross margin | 63.6% | 62.9% | 60.2% | 62.2% | 62.7% | 63.8% | 63.9% | 61.4% |
| Operating income | 132,401 | 84,425 | 99,439 | 129,163 | 121,902 | 115,347 | 119,098 | 112,103 |
| Net income | 103,401 | 68,043 | 107,829 | 130,043 | 96,250 | 90,758 | 88,322 | 98,056 |
| EPS, diluted | 0.50 | 0.33 | 0.49 | 0.60 | 0.44 | 0.41 | 0.39 | 0.44 |
| = Free cash flow | 157,760 | 53,746 | 117,220 | 118,974 | 121,245 | 95,838 | 142,818 | 138,638 |
What should QIAGEN watch in the next results?
The November 4 results should show whether customers paid promptly, inventories absorbed cash and restructuring required more payments. They will also replace preliminary sales and EPS with a fuller view of the quarter.